Takeda scraps late-stage amyloidosis study

 Takeda scraps late-stage amyloidosis study

(Reuters) - Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Amyloidosis is a rare disease caused by an abnormal build up of a substance called amyloid in organs.

Treatment with Takeda's Ninlaro, in combination with dexamethasone, did not show a significant improvement in patients' overall hematologic response compared to standard of care regimens, the company said.

U.S.-listed shares of Takeda were down about 2% at $16.5 in after-hours trading.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by James Emmanuel)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date: Jun 06, 2019 03:07:32 IST